EVA Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High Human Immunodeficiency Virus (HIV) Incidence and Limited Resources

 

EVA Pharma (www.EVAPharma.com) announced today a non-exclusive, royalty-free voluntary licensing agreement signed with Gilead (https://apo-opa.co/4dB3Nwx), allowing EVA Pharma to manufacture and supply generic lenacapavir in form of active pharmaceutical ingredient and finished pharmaceutical product. This agreement includes the technology transfer of know-how to make and use lenacapavir allowing for sustainable accessibility to lenacapavir in 120 high-incidence, resource-limited countries through EVA Pharma’s local manufacturing capabilities and strong foothold in Africa.

The agreement covers lenacapavir for HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug-resistant HIV, as well as lenacapavir for HIV prevention (pending approval). Gilead is exploring frameworks such as the European Medicines Agency’s EU Medicines for All with the aim of expediting both U.S. FDA procedures and the attainment of WHO prequalification. This will enable EVA Pharma to submit its high-quality generic lenacapavir for multiple regulatory authorities to support demand and broaden accessibility across 120 countries.

“The urgency of NOW (https://apo-opa.co/3zLMw5Q) demands that we go fast and far to end HIV/AIDS. This goal is only reached through collective efforts, from innovation to sustainable access to medicines.” said Riad Armanious, CEO of EVA Pharma. “To this commitment we stand our ground as the sole licensee on Africa, EVA Pharma has already rolled the ball on fast-track actions towards our joint mission with Gilead. Combining Gilead’s expertise and EVA Pharma’s capabilities and reach we ensure that no one is left behind in the fight against HIV.”

“EVA Pharma has been committed to the fight against HIV since 2003, consistently empowering governments and healthcare systems to support patient care across Africa” said Amgad Talaat, Strategic Alliances Director at EVA Pharma. “In our ongoing effort to ensure sustainable access, EVA Pharma has expanded its focus to localizing drug substance production. In collaboration with Gilead we have been setting numerous firsts in the area of generic voluntary licensing, from combatting HCV to making remdesivir available for COVID patients. And now, we embark on another significant milestone by supplying lenacapavir to patients across the continent, including South Africa for the first time”

Of the six generic manufacturers in Gilead’s voluntary licensing agreement, EVA Pharma is the sole local manufacturer in Africa. Responding to the urgency of this shared mission, EVA Pharma expects to complete lenacapavir API manufacturing by the end of 2024, following the completion of the tech-transfer from Gilead, paving the way for the production of lenacapavir finished product. The company expects to begin supplying the high-quality, African-made lenacapavir within 25 months. Leveraging its extensive pan-African reach, EVA Pharma will supply the medicine to 120 countries, with the first phase of export including 18 countries representing the highest incidence rate (about 70% of the HIV burden in the countries named in the license) to receive lenacapavir as quickly as possible. These countries are Botswana, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Philippines, Rwanda, South Africa, Tanzania, Thailand, Uganda, Vietnam, Zambia and Zimbabwe.

Distributed by APO Group on behalf of EVA Pharma.

Media Contact:
Ahmed Ellewa
ahmed.ellewa@evapharma.com
+20-1000-053-643
(EVA Pharma Media)

Marina Mansour
marina.mansour@evapharma.com
(EVA Pharma Media)

Follow us on:
Facebook: https://apo-opa.co/3NbghQz
LinkedIn: https://apo-opa.co/3zWZ3Dw
Instagram: https://apo-opa.co/3XQFqFe

About EVA Pharma:
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic product.

With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.

Guided by a relentless drive to ensure sustainable access to pressing, yet unmet, disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.

EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.

For more information, please visit: www.EVAPharma.com&https://apo-opa.co/3XVhbG9

About Gilead Sciences:
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

About Lenacapavir:
Lenacapavir is approved in multiple countries for the treatment of adults with multi-drug-resistant HIV in combination with other antiretrovirals. The use of lenacapavir for HIV prevention is investigational and the safety and efficacy of lenacapavir for this use have not been established.

The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes.

Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead’s HIV prevention and treatment research program. Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address individual needs and preferences of people and communities affected by HIV.